AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39521467 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow only weaning
Number of subjects: 20
Study 39521467 — intervention group
Group type: COMPARATOR
Intervention: Standard oxygen therapy
Number of subjects: 20
Study 39521475 — intervention group
Group type: EXPERIMENTAL
Intervention: Differential target multiplexed spinal cord stimulation (DTM SCS)
Number of subjects: 250
Study 39521698 — intervention group
Group type: EXPERIMENTAL
Intervention: Coated miniscrews with chlorhexidine hexametaphosphate antimicrobial nanoparticles
Number of subjects: 40
Study 39521698 — intervention group
Group type: COMPARATOR
Intervention: Uncoated miniscrews
Number of subjects: 40
Study 39521698 — intervention group
Group type: EXPERIMENTAL
Intervention: Coated miniscrews
Number of subjects: 40
Study 39521897 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based educational intervention about cooking-related pollutants and range hood replacement
Number of subjects: 14
Study 39521970 — intervention group
Group type: EXPERIMENTAL
Intervention: A.S.K.-PrEP
Number of subjects: 250
Study 39521970 — intervention group
Group type: EXPERIMENTAL
Intervention: A.S.K.-PrEP + Contingency Management (CM)
Number of subjects: 250
Study 39521970 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM) alone
Number of subjects: 250
Study 39521970 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 250
Study 39522003 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-Cr conventional casting bar
Number of subjects: 30
Study 39522003 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-Cr CAD/CAM milled bar
Number of subjects: 30
Study 39522003 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-Cr CAD/CAM 3D-printed bar
Number of subjects: 30
Study 39522018 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation intervention (8 tele-therapy sessions over 10 weeks)
Number of subjects: 15
Study 39522090 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase (low- or high-dose) plus standard of care (SOC)
Number of subjects: 104
Study 39522090 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) alone
Number of subjects: 104
Study 39522476 — intervention group
Group type: EXPERIMENTAL
Intervention: Connective tissue massage
Number of subjects: 57
Study 39522476 — intervention group
Group type: COMPARATOR
Intervention: Sham therapeutic ultrasound
Number of subjects: 57
Study 39522541 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant toripalimab (240 mg intravenously) every 2 weeks for two cycles followed by concurrent cisplatin (100 mg/m2)
Number of subjects: 150
Study 39522541 — intervention group
Group type: COMPARATOR
Intervention: Placebo with concurrent cisplatin (100 mg/m2)
Number of subjects: 150
Study 39522541 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant toripalimab
Number of subjects: 150
Study 39522541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 39522584 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC) for 28 days
Number of subjects: 42
Study 39522584 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention for 28 days
Number of subjects: 42
Study 39522584 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC)
Number of subjects: 42
Study 39522584 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 42
Study 39522630 — intervention group
Group type: EXPERIMENTAL
Intervention: mLife+points
Number of subjects: 240
Study 39522630 — intervention group
Group type: COMPARATOR
Intervention: mLife
Number of subjects: 240
Study 39522641 — intervention group
Group type: EXPERIMENTAL
Intervention: sTIL levels in metastases
Number of subjects: 20
Study 39522641 — intervention group
Group type: EXPERIMENTAL
Intervention: sTIL levels in metastases from invasive lobular carcinoma
Number of subjects: 20
Study 39522641 — intervention group
Group type: EXPERIMENTAL
Intervention: ER expression in metastases
Number of subjects: 20
Study 39522641 — intervention group
Group type: EXPERIMENTAL
Intervention: sTIL levels in lung and axillary lymph node metastases
Number of subjects: 20
Study 39522654 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlitelimab 250 mg every 4 weeks plus a 500-mg loading dose
Number of subjects: 390
Study 39522654 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlitelimab 125 mg every 4 weeks
Number of subjects: 390
Study 39522654 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlitelimab 62.5 mg every 4 weeks
Number of subjects: 390
Study 39522654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390
Study 39522654 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlitelimab (any dose) continued for 28 weeks after initial treatment
Number of subjects: 390
Study 39522654 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlitelimab (any dose) stopped after initial treatment
Number of subjects: 390
Study 39522654 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlitelimab (any dose)
Number of subjects: 390
Study 39522714 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoanalgesia
Number of subjects: 103
Study 39522714 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 103
Study 39522752 — intervention group
Group type: EXPERIMENTAL
Intervention: Ophthalmologists
Number of subjects: 134
Study 39522752 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated AI-based analysis
Number of subjects: 134
Study 39522752 — intervention group
Group type: COMPARATOR
Intervention: Sham arm
Number of subjects: 134
Study 39522752 — intervention group
Group type: COMPARATOR
Intervention: Untreated fellow eyes
Number of subjects: 134
Study 39522824 — intervention group
Group type: EXPERIMENTAL
Intervention: eRT (FDG-PET-guided dose painting and scheduled adaptive radiotherapy)
Number of subjects: 221
Study 39522957 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4-mg equivalent
Number of subjects: 467
Study 39522957 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 2-mg equivalent
Number of subjects: 467
Study 39522957 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 1-mg equivalent
Number of subjects: 467
Study 39522957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 467
Study 39523312 — intervention group
Group type: EXPERIMENTAL
Intervention: NeoSealer Flo
Number of subjects: 120
Study 39523312 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA-Bioseal
Number of subjects: 120
Study 39523312 — intervention group
Group type: EXPERIMENTAL
Intervention: GuttaFlow bioseal
Number of subjects: 120
Study 39523312 — intervention group
Group type: EXPERIMENTAL
Intervention: AH Plus epoxy resin-based sealer
Number of subjects: 120
Study 39523352 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-determination (GSD) intervention
Number of subjects: 0
Study 39523352 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 0
Study 39523406 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification intervention program, MyBFF@school Phase I (16 weeks) including physical activity, healthy eating promotion, and psychological empowerment.
Number of subjects: 102
Study 39523423 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength and power training (n=18)
Number of subjects: 37
Study 39523423 — intervention group
Group type: COMPARATOR
Intervention: Strength training (n=19)
Number of subjects: 37
Study 39523543 — intervention group
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir/ritonavir (NMV/r) 300 mg/100 mg every 12 hours for 5 days
Number of subjects: 1966
Study 39523543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1966
Study 39523547 — intervention group
Group type: EXPERIMENTAL
Intervention: RSVpreF (120 µg)
Number of subjects: 678
Study 39523547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 678
Study 39523681 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease Severity Index (DSI) calculated from clearances of labelled cholates after oral and intravenous administration
Number of subjects: 306
Study 39523681 — intervention group
Group type: EXPERIMENTAL
Intervention: Using DSI ≤ 18.3 as the sole determinant to defer EGD
Number of subjects: 306
Study 39523874 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase-facilitated subcutaneous immunoglobulin (fSCIG) 10% administered every 4 weeks (88.2%) or every 3 weeks (11.8%). Median 4-weekly IgG dose equivalent was 64.0 g (range 28.0-200.0 g).
Number of subjects: 85
Study 39523874 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 85
Study 39523878 — intervention group
Group type: EXPERIMENTAL
Intervention: Three standard doses of inactivated COVID-19 vaccines
Number of subjects: 182
Study 39523878 — intervention group
Group type: EXPERIMENTAL
Intervention: Two standard doses plus a double dose of inactivated COVID-19 vaccines
Number of subjects: 182
Study 39523878 — intervention group
Group type: COMPARATOR
Intervention: Two doses of inactivated COVID-19 vaccines in healthy controls
Number of subjects: 182
Study 39523954 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (30-50 min low-to-high intensity exercise 5 times/week for 8 weeks, starting one day after discharge)
Number of subjects: 55
Study 39523954 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 55
Study 39524040 — intervention group
Group type: EXPERIMENTAL
Intervention: Andexanet alfa
Number of subjects: 250
Study 39524040 — intervention group
Group type: COMPARATOR
Intervention: Four-factor prothrombin complex concentrate (4F-PCC)
Number of subjects: 250
Study 39524078 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral load testing and suppression education
Number of subjects: 32
Study 39524078 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to ART
Number of subjects: 32
Study 39524078 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement with healthcare providers
Number of subjects: 32
Study 39524078 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiences with viral load testing
Number of subjects: 32
Study 39524078 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to viral suppression
Number of subjects: 32
Study 39524230 — intervention group
Group type: EXPERIMENTAL
Intervention: Acalabrutinib + Obinutuzumab
Number of subjects: 0
Study 39524230 — intervention group
Group type: EXPERIMENTAL
Intervention: Acalabrutinib (monotherapy)
Number of subjects: 0
Study 39524230 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil + Obinutuzumab
Number of subjects: 0
Study 39525336 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical decision support system
Number of subjects: 1133
Study 39525336 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 1133
Study 39525351 — intervention group
Group type: EXPERIMENTAL
Intervention: Microfracture (MFx)
Number of subjects: 36
Study 39525351 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine-derived collagen-augmented chondrogenesis technique (C-ACT)
Number of subjects: 36
Study 39525351 — intervention group
Group type: COMPARATOR
Intervention: C-ACT
Number of subjects: 36
Study 39525672 — intervention group
Group type: EXPERIMENTAL
Intervention: PIKA COVID-19 vaccine booster dose
Number of subjects: 0
Study 39525672 — intervention group
Group type: COMPARATOR
Intervention: Inactivated COVID-19 vaccine (Sinovac, China)
Number of subjects: 0
Study 39525677 — intervention group
Group type: EXPERIMENTAL
Intervention: PIKA-adjuvanted recombinant SARS-CoV-2 spike protein subunit vaccine (5 µg, 10 µg, and 20 µg)
Number of subjects: 0
Study 39525677 — intervention group
Group type: EXPERIMENTAL
Intervention: PIKA-adjuvanted recombinant SARS-CoV-2 spike protein subunit vaccine
Number of subjects: 0
Study 39525828 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Bundle Branch Area Pacing (LBBAP)
Number of subjects: 0
Study 39525828 — intervention group
Group type: COMPARATOR
Intervention: Right Ventricular Septal Pacing (RVSP)
Number of subjects: 0
Study 39525834 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth support for 6 months
Number of subjects: 34
Study 39525834 — intervention group
Group type: COMPARATOR
Intervention: Standard physical education classes
Number of subjects: 34
Study 39525874 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance Group (DG)
Number of subjects: 77
Study 39525874 — intervention group
Group type: EXPERIMENTAL
Intervention: Martial Arts Group (MaG)
Number of subjects: 77
Study 39525874 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 77
Study 39525887 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous tissue of lipedema stages I, II, and III
Number of subjects: 29
Study 39525887 — intervention group
Group type: COMPARATOR
Intervention: Hypertrophied subcutaneous tissue
Number of subjects: 29
Study 39525940 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT) using the Sanvello smartphone application for 4 weeks
Number of subjects: 0
Study 39525940 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39526078 — intervention group
Group type: EXPERIMENTAL
Intervention: Etrasimod (2 mg or 1 mg, once daily)
Number of subjects: 943
Study 39526078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 943
Study 39526177 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Palliative Care (EPC) plus standard oncological care (SOC)
Number of subjects: 470
Study 39526177 — intervention group
Group type: COMPARATOR
Intervention: Standard Oncological Care (SOC) alone
Number of subjects: 470
Study 39526355 — intervention group
Group type: EXPERIMENTAL
Intervention: CDC infusion
Number of subjects: 93
Study 39526563 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk intake (AHM)
Number of subjects: 447
Study 39526563 — intervention group
Group type: COMPARATOR
Intervention: Formula only (FO)
Number of subjects: 447
Study 39526777 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (FDG-PET/CT)
Number of subjects: 40
Study 39526777 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up MRI
Number of subjects: 40
Study 39526777 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroencephalography
Number of subjects: 40
Study 39526777 — intervention group
Group type: EXPERIMENTAL
Intervention: Abscess capsule FDG signal
Number of subjects: 40
Study 39526779 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose 5-ALA (>40 mg/kg)
Number of subjects: 31
Study 39526779 — intervention group
Group type: COMPARATOR
Intervention: Low/standard dose 5-ALA (<30 mg/kg)
Number of subjects: 31
Study 39526836 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative nursing care intervention
Number of subjects: 144
Study 39526855 — intervention group
Group type: EXPERIMENTAL
Intervention: Low salt diet (1.5 g/day) for 3 months
Number of subjects: 194
Study 39526855 — intervention group
Group type: COMPARATOR
Intervention: Usual diet (control group)
Number of subjects: 194
Study 39527055 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 66
Study 39527055 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 66
Study 39527055 — intervention group
Group type: EXPERIMENTAL
Intervention: TMS-induced electric field strength
Number of subjects: 66
Study 39527056 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronate (5 mg) in the first year
Number of subjects: 101
Study 39527056 — intervention group
Group type: COMPARATOR
Intervention: Continuous denosumab treatment (60 mg twice yearly)
Number of subjects: 101
Study 39527056 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronate (5 mg) in the first year (ZOL subgroup with 3 or more years of denosumab treatment)
Number of subjects: 101
Study 39527097 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab, trastuzumab, and anti-CTLA-4 ipilimumab (Ipi arm)
Number of subjects: 0
Study 39527097 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab, trastuzumab, and FOLFOX chemotherapy (FOLFOX arm)
Number of subjects: 0
Study 39527163 — intervention group
Group type: EXPERIMENTAL
Intervention: OroSEP
Number of subjects: 341
Study 39527163 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 341
Study 39527236 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper Extremity Robotic Rehabilitation (RR) - ExoRehab X, Houston Bionics, twice/week for 6 weeks alongside conventional treatment.
Number of subjects: 34
Study 39527236 — intervention group
Group type: COMPARATOR
Intervention: Conventional Rehabilitation (CR) - 5 days/week for 6 weeks.
Number of subjects: 34
Study 39527236 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CR and RR)
Number of subjects: 34
Study 39527466 — intervention group
Group type: EXPERIMENTAL
Intervention: Darolutamide plus ADT and docetaxel
Number of subjects: 148
Study 39527466 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus ADT and docetaxel
Number of subjects: 148
Study 39527516 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) intervention over 4 weeks
Number of subjects: 90
Study 39527516 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 90
Study 39527516 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) intervention
Number of subjects: 90
Study 39527532 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTIVE (online exercise intervention)
Number of subjects: 32
Study 39527532 — intervention group
Group type: COMPARATOR
Intervention: CON (waitlist control)
Number of subjects: 32
Study 39527705 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital platform for recurrent UTI management
Number of subjects: 31
Study 39527960 — intervention group
Group type: EXPERIMENTAL
Intervention: Betibeglogene autotemcel (beti-cel) gene therapy
Number of subjects: 18
Study 39527970 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 1039
Study 39527970 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 1039
Study 39528049 — intervention group
Group type: EXPERIMENTAL
Intervention: First Subsequent Therapy (FST) with platinum-based chemotherapy and PARP inhibitor
Number of subjects: 806
Study 39528058 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol 200 mg plus EGb 761 160 mg daily
Number of subjects: 500
Study 39528058 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 100 mg and clopidogrel 75 mg daily
Number of subjects: 500
Study 39528108 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blockers
Number of subjects: 806
Study 39528111 — intervention group
Group type: EXPERIMENTAL
Intervention: Solriamfetol (75 mg/d for 3 days, then 150 mg/d for 2 weeks)
Number of subjects: 59
Study 39528111 — intervention group
Group type: EXPERIMENTAL
Intervention: Solriamfetol
Number of subjects: 59
Study 39528111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 39528324 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir amibufenamide therapy
Number of subjects: 0
Study 39528324 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39528323 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir amibufenamide
Number of subjects: 0
Study 39528323 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39528478 — intervention group
Group type: EXPERIMENTAL
Intervention: lenalidomide-bortezomib-dexamethasone (RVd) induction for ≥3 cycles
Number of subjects: 633
Study 39528489 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab (Isa) 20-mg/kg administered weekly in cycle 1, then biweekly
Number of subjects: 21
Study 39528665 — intervention group
Group type: EXPERIMENTAL
Intervention: AUTO4 (TRBC1-directed autologous chimeric antigen receptor T cells)
Number of subjects: 10
Study 39528780 — intervention group
Group type: EXPERIMENTAL
Intervention: Community exercise programmes
Number of subjects: 64
Study 39528916 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-week multimodal prehabilitation program
Number of subjects: 112
Study 39528916 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical care (control group)
Number of subjects: 112
Study 39528951 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 44
Study 39528997 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored exercise and nutrition program for six months
Number of subjects: 182
Study 39528997 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 182
Study 39528997 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition program adherence measured by MEDAS
Number of subjects: 182
Study 39528997 — intervention group
Group type: EXPERIMENTAL
Intervention: Malnutrition risk assessed by NRS2002
Number of subjects: 182
Study 39528997 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQoL)
Number of subjects: 182
Study 39529032 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led aftercare programme (pre-discharge support and proactive follow-up support over 8 weeks)
Number of subjects: 60
Study 39529032 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 60
Study 39529054 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg of CAF/kg
Number of subjects: 26
Study 39529054 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg of CAF/kg
Number of subjects: 26
Study 39529054 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 mg of CAF/kg
Number of subjects: 26
Study 39529054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 39529061 — intervention group
Group type: EXPERIMENTAL
Intervention: FSI-ECD + VP
Number of subjects: 160
Study 39529061 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 160
Study 39529079 — intervention group
Group type: EXPERIMENTAL
Intervention: Rezafungin
Number of subjects: 294
Study 39529079 — intervention group
Group type: COMPARATOR
Intervention: Caspofungin
Number of subjects: 294
Study 39529089 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted facilitation of the Mothers and Babies intervention
Number of subjects: 0
Study 39529089 — intervention group
Group type: COMPARATOR
Intervention: Implementation as usual (standard education)
Number of subjects: 0